Substance / Medication

Kanamycin sulfate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical options.
Sfoungaristos Stavros, Gofrit Ofer N, Yutkin Vladimir et al. · Expert Opin Pharmacother · 2015
PMID: 25881654Meta-Analysis
Strategy to control catheter encrustation with citrated drinks: a randomized crossover study.
Khan Azhar, Housami Fadi, Melotti Roberto et al. · J Urol · 2010
PMID: 20171661RCT
[Research progress of acute kanamycin sulfate-induced deafness in guinea pig].
Yin Zedeng, Kng Weijia · Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2012
PMID: 22870728Review
Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis.
Tatsumi Ryoji, Suii Hirokazu, Yamaguchi Masakatsu et al. · Intern Med · 2021
PMID: 33361677OtherFull text (PMC)
Carbon dots derived from kanamycin sulfate with antibacterial activity and selectivity for Crdetection.
Luo Qian, Qin Kunhao, Liu Fei et al. · Analyst · 2021
PMID: 33496685Other
PCN-222@g-CNcathodic materials for "signal-off" photoelectrochemical sensing of kanamycin sulfate.
Dong Wenxia, Li Zhongping, Wen Wen et al. · RSC Adv · 2021
PMID: 35480742OtherFull text (PMC)
An edible kanamycin sulfate cross-linked cellulose active against multiple pathogenic bacteria.
Gu Jun, Zhang Shuaifeng, Xia Xuefeng et al. · Int J Biol Macromol · 2022
PMID: 34801585Preclinical
[Ototoxicity of kanamycin sulfate in adult rats and its underlying mechanisms].
Zhang Zhi-Cun, Yu Hong-Meng, Liu Quan et al. · Sheng Li Xue Bao · 2011
PMID: 21505733Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Kanamycin sulfate (substance)
SNOMED CT
8689007
UMLS CUI
C0700540

Clinical Data

This intervention maps to 11 entities in the Healos knowledge graph.

11
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.